Brief: Genmab Says Phase 3 EPCORE FL-1 Clinical Trial Met Dual Primary Endpoints In Patients With R/R FL

Genmab A/S

07/08/2025 16:34

Aug 7 (Reuters) - Genmab A/S GMAB.CO:

GENMAB ANNOUNCES PHASE 3 EPCORE® FL-1 CLINICAL TRIAL MET DUAL PRIMARY ENDPOINTS IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)

GENMAB - FDA HAS ACCEPTED FOR PRIORITY REVIEW NEW SBLA FOR EPCORITAMAB PLUS R(2), WITH ACTION DATE OF NOVEMBER 30

Source text: ID:nGNX2rWWnk

Further company coverage: GMAB.CO

 ((Reuters.Briefs@thomsonreuters.com;))